Not exact matches
Dr. De Vivo emphasized that in developing drugs for orphan diseases such as
SMA, collaborative programs are a must, and that «strong relationships with disease advocacy
foundations are absolutely key.»
PsychoGenics works with pharmaceutical and biotechnology companies, academic institutions and not - for - profit research
foundations to address such major neurological disorders as: ALS, Huntington's Disease, anxiety, cognitive impairment, depression, psychosis / schizophrenia and
SMA.
In accepting the award on behalf of the Foundation, Executive Director Cynthia Joyce thanked Dr. De Vivo and the many child neurology specialists who have cared for children with
SMA and advised
foundations over the years.
«We are discussing the merits of this compound, the [
SMA] Project and its assets with a whole panel of external interested parties —
foundations as well as companies — to see if we can establish a licensing agreement where this could be developed further,» says Rajan Ranganathan, head of the NINDS's Office of Translational Research.